BALTIMORE, July 30 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today that it received the award for “Best New Manufacturer of the Year, Generics Rx” from AmerisourceBergen, a leader in healthcare distribution in the US. The award is in recognition of Lupin’s contribution and commitment toward excellence as a Generic drug supplier in the US.
Commenting on the award, Vinita Gupta, President and Managing Director of Lupin Pharmaceuticals, Inc. said, “We are very pleased with the recognition that Lupin has received from AmerisourceBergen.” Ms. Gupta added, “Lupin launched its Generics Rx division in December 2005 and this award is a reflection of our continued and unwavering commitment to our customers in identifying, filing, launching and supplying important generic products.”
About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with a strong research focus. It has a program for developing New Chemical Entities. The Company has a state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDs and Asthma.
For the financial year ended March 2007, the Lupin’s Revenues and Profit after Tax were Rs.20,289 million (US$ 475 million) and Rs.3,021 million (US$ 70 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com .
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management’s expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.
For More Information Contact: Edith St-Hilaire Senior Marketing Manager 410-576-2000
Lupin Pharmaceuticals, Inc.
CONTACT: Edith St-Hilaire, Senior Marketing Manager of LupinPharmaceuticals, Inc., +1-410-576-2000
